1. Introduction {#s0005}
===============

Fabry disease (OMIM \#[301500](301500){#ir0005}) is an X-linked disorder characterized by the deficiency of the lysosomal hydrolase α-galactosidase A (α-gal A, E.C. 3.2.1.22) due to mutations in the *GLA* gene \[[@bb0005],[@bb0010]\]. Patients with partial or complete deficiency of α-gal A are unable to degrade glycosphingolipids, such as globotriaosylceramide (Gb3), and related glycosphingolipids, such as globotriaosylsphingosine (Lyso-Gb3), effectively, and these lipids consequently accumulate in body fluids and the lysosomes of a variety of cell types, including the vascular endothelium, kidney, heart, eye, and nerve cells \[[@bb0015],[@bb0020]\].

Clinical manifestations in classically affected hemizygotes who have no detectable α-gal A activity include pain and paresthesia in the extremities, angiokeratoma, and hypo- or anhidrosis. Corneal and lenticular opacities are also early findings. With increasing age, proteinuria, hyposthenuria, and lymphedema appear \[[@bb0010]\]. Severe renal impairment leads to hypertension and uremia. Death usually occurs from renal failure or cardiac or cerebrovascular disease \[[@bb0005]\].

The clinical course and prognosis of heterozygous females differ from those of hemizygotes \[[@bb0025]\]. Approximately 70% of heterozygous Caucasians have whorl-like corneal dystrophy as an early manifestation of the disease \[[@bb0030],[@bb0035]\]. However, Japanese female Fabry patients have a heterogeneous presentation. The age at onset of disease varies from 4 to 68 years. \>50% of the heterozygotes present with acroparesthesia and corneal opacities. Approximately 40% of the patients have proteinuria and left ventricular hypertrophy (LVH). The incidence of LVH in women over 68 years of age is approximately 100% \[[@bb0040]\]. The diagnoses of heterozygous females are also complicated because of residual α-Gal A activity \[[@bb0045]\]. Even genetic testing of at-risk patients or patients suspicious for Fabry disease has been compromised by the recently recognized occurrence of various benign missense mutations \[[@bb0050], [@bb0055], [@bb0060]\].

Various Fabry disease severity scoring systems, such as the Mainz Severity Score Index (MSSI) \[[@bb0065]\], the Fabry Disease Severity Scoring System (DS3) \[[@bb0070]\] provide an index of disease severity at a single time point. In our daily practice in Japan, the FAbry STabilization indEX (FASTEX) \[[@bb0075]\] is commonly used as a mathematical model in order to objectively verify the clinical severity and stability of patients with Fabry disease.

The pathophysiology for the severity of phenotypes in heterozygous Fabry females is still poorly understood. XCI occurs at random within females resulting in an average inactivation ratio of 50:50 with normal distribution \[[@bb0080]\]. Skewed XCI is described for some other diseases \[[@bb0085]\]. The existence of skewed XCI in females with Fabry disease was found in a recent study by analyzing the human androgen receptor (*HUMARA*) gene \[[@bb0090]\] which demonstrated the existence of skewed inactivation (29%) of heterozygotes females with Fabry disease correlating to Fabry disease severity scores (MSSI and DS3).

In higher order eukaryotes, DNA is methylated only at 5'-CpG-3′ dinucleotides (CpGs), and this DNA modification has important regulatory effects on gene expression, especially in CpG-rich areas (known as CpG islands) located in the promoter regions of many genes \[[@bb0095], [@bb0100], [@bb0105]\]. As extensive methylation of CpG islands is associated with transcriptional inactivation of several genes on one of the two X-chromosomes in females \[[@bb0110],[@bb0115]\], such X chromosomes result in an inactive condition. XCI is accompanied by the changes in DNA methylation at CpG islands, and the methylation of *Hpa*II and *Hha*I sites correlates with XCI \[[@bb0120],[@bb0125]\]. The 5'UTR of the *GLA* gene contains a CpG island composed of 474 base pairs (chrX:101407840--101,408,313) \[[@bb0130]\]. Our previous study showed that the methylation of *Hpa*II and *Hha*I sites in exon 1 of *GLA* correlates with XCI and the severity of the disease \[[@bb0135]\].

In this study, we summarized 36 heterozygous Fabry females with their clinical severity score and detected their lyso-Gb3 accumulation in plasma and sphingolipid accumulation with skin biopsies. We obtained the methylation-sensitive restriction enzyme sites (*RE*) in exon 1, 5'UTR and exon 7 of the *GLA* gene. We found a clear correlation between the severity of the phenotype, lyso-Gb3 accumulation and methylation of the normal allele detected by nondigestion with methylation-sensitive RE *Sac*II, *Hha*I and *Hpa*II.

2. Materials and methods {#s0010}
========================

2.1. Patients\' clinical summary {#s0015}
--------------------------------

The information of the 36 heterozygous Japanese Fabry females was summarized based on their previous family history, careful physical examinations, and biochemical and molecular findings. The findings were then categorized to fit FASTEX scoring including the nervous, cardiac and renal systems.

2.2. Calculation of the clinical severity score by FASTEX {#s0020}
---------------------------------------------------------

The FASTEX score was calculated as described before \[[@bb0075]\] with some modification. In short, nervous events included pain and other neural events; cardiac events included LVH, ECG/arrhythmia and cardiac functioning categorized by the New York Heart Association (NYHA), and renal events included the albumin-creatinine ratio (ACR)/protein-creatinine ratio (PCR) and eGFR. One of seven events ranged from 0--4. The total raw score was then summed.

2.3. Measurement of α-gal a activity using 4MUGal substrate {#s0025}
-----------------------------------------------------------

The level of α-gal A activity was measured as previously reported \[[@bb0140]\]. In short, lymphocytes and skin fibroblasts (SFs) were sonicated, and the whole cell lysates were incubated with a mixture containing 700 mM 4-methylumbelliferyl-α-[d]{.smallcaps}-galactopyranoside (4 MUGal; Sigma), 0.5 M *N*-acetyl-[d]{.smallcaps}-galactosamine (GalNAc; Sigma), and 50 mM citrate-phosphate (pH 4.5) buffer in a water bath at 37 °C for 3 h. The reactions were stopped with 150 mM ethylenediaminetetraacetic acid (pH 11.5) buffer. The fluorescence (excitation at 355 nm/emission at 460 nm) was measured with a microplate reader. The enzyme activity was calculated as nmol·h^−1^·mg protein^−1^.

2.4. Quantification of lyso-Gb3 by liquid chromatography-tandem mass spectrometry (LC-MS/MS) {#s0030}
--------------------------------------------------------------------------------------------

Quantification of lyso-Gb3 was performed as described before \[[@bb0140]\]. In short, 60 μL fresh plasma was separated from whole blood and placed into a 1.5 mL tube containing 540 μL 2-propanol (HPLC-grade, Kanto, Japan) and 20 μL internal standard. After mixing for 2 min with a microtube mixer (Tommy, Japan), the extraction was centrifuged for 20 min at 12,000*g*. The supernatant from the extraction was dried under an air stream and reconstituted with 20 μL methanol. The final solution was transferred to autosampler micro vials for measurement by the LCMS-8040 system (Shimadzu, Japan).

The calibration set consisted of LysoGb3 (Matreya LLC, USA) standards with the same amount of N-glycinated LysoGb3 (internal standard, Matreya LLC, USA) in the methanol solvent. The calibrated amount of LysoGb3 was 0.0--0.8 ng (R^2^ = 0.996), and a calibration set was performed for every 50 samples.

Five microliters of the solution were measured by high-performance liquid chromatography (HPLC) connected to a tandem mass spectrometer (LCMS-8040, Shimadzu, Japan). The mixture was eluted with mobile phase A (10 mM NH~4~COOH, Wako, Japan) and phase B (10% 10 mM NH~4~COOH/MeOH) through a C8 column (Inertsil C8--3, 3 μm, 2.1 × 50 mm, GL Sciences Inc., Japan) connected to an in-line filter unit (ACQUITY, Waters, USA). The multiple reaction monitoring (MRM) transitions monitored were 786.5 \> 264.3 *m*/*z* for LysoGb3 and 843.5 \> 264.3 m/z for N-glycinated LysoGb3. The quantification of LysoGb3 was performed by comparing the peak molecular target area with the internal standard area.

2.5. Electron microscopy of skin biopsies {#s0035}
-----------------------------------------

Electron microscopy for skin biopsies for cases 1--5, 7, 12--16, 18, 27--28 was done as described before \[[@bb0145]\]. In short, a 2 mm skin punch was taken from the left elbow, and small blocks of tissue were fixed in 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.2). Some blocks were directly embedded in Epon or glycol methacrylate. Ultrathin sections were examined either unstained or after various treatments: uranyl acetate and lead citrate, periodic acid‑silver methenamine, periodic acid-thiocarbohydrazide‑silver proteinate (PA-TCH-SP), and hydrogen peroxide-phosphotungistic acid (H~2~0~2~-PTA).

2.6. Detection of methylation sensitivity for *Sac*II, *Hha*I and *Hpa*II sites in the GLA gene {#s0040}
-----------------------------------------------------------------------------------------------

Methylation-sensitive sites were detected as described before \[[@bb0135]\]. In short, DNA from peripheral blood and SFs was collected using the Qiagen blood and tissue kit (Cat. No. 69504) and an amount of 400 to 1200 ng of DNA was used for bisulfite modification following the MethylEasy Xceed (Human Genetic Signatures Pty Ltd) protocol. Bisulfite-modified DNA, 40 to 50 ng, was amplified for each exon and the 5'UTR of the *GLA* gene with respective primer sets. The amplified DNA was then purified and sequenced.

2.7. Quantification of methylation of each allele in the GLA gene {#s0045}
-----------------------------------------------------------------

One microgram of DNA from peripheral blood and SFs containing *Sac*II was incubated for 20 h at 37 °C. The digested DNA was then purified by a high pure PCR product purification kit (ref. 11,732,676,001). Purified DNA fragments were used for long PCR amplification with PrimeSTAR GXL (Takara cat\# R050A). A pair of primers (forward 5'-AGCGAGACGGTAGACGACGACCAGAACTACTTC-3′, reverse 5'-GGGGTGGGTATCTGGATGAGTAAATATGGGTT-3′) was used to amplify the whole *GLA* gene 11 kb including the 5'UTRA for all the cases. For *Hha*I and *Hpa*II sites, 200 ng of DNA were used for the digestion reaction. Purified DNA fragments were used for amplification of exon 1 of the *GLA* gene for cases 1--9, 32 and 35--36 who had exon 1 mutations by the primers described before \[[@bb0135]\]. For other cases that had exon 5--7 mutations, exons 5 to 7 were amplified. All amplified PCR fragments were purified by Wizard SV gel and PCR (Promega), and direct sequencing was performed.

Quantification of methylation was performed based on digestion of mutated or non-mutated alleles by methylation-sensitive restriction enzymes. The quantification of methylation was measured by the Mutation Surveyor Softgenetics software (version 5.1.0). In short, the calculation of methylation of the non-mutated allele was performed in digested fragments as the length of non-mutated allele/ (length of mutated allele+ length of non-mutated allele).

3. Results {#s0050}
==========

3.1. Clinical characteristics of heterozygous Fabry females {#s0055}
-----------------------------------------------------------

The clinical presentations were widely varied. Some cases were found to have no phenotype, e.g., cases 22, 24--25, 31, 33--36, and some cases were showing a severe phenotype as Hemizygous Fabry males, e.g., cases 1, 4--10, 12--13, 16, 23, 26--28, 30.

3.2. Calculation of the FASTEX score {#s0060}
------------------------------------

Based on the clinical characteristics, the FASTEX raw score was summed. Most of the heterozygous female scores (21/36) ranged from 5 to 21. Some of them scored \<5, e.g., case 3, 4, 11, 17--20, 22, 24--25, 31, 33--36.

3.3. α-gal A activity {#s0065}
---------------------

Whole cell lysates from blood lymphocytes and SFs were used to detect α-gal A activity. The enzyme activity was widely varied and irrelevant to clinical severity, and it is listed in [Table 1](#t0005){ref-type="table"}.Table 1Summary of patients\' clinical, biochemical and genetic informationTable 1Patient No.AgeMajor clinical characteristicsα-gal A activity[a](#tf0005){ref-type="table-fn"}Plasma lyso-Gb3[b](#tf0010){ref-type="table-fn"}FASTEX Raw ScoreMethylation of normal (non-mutated) allele (%)*GLA* genotypesReference (*GLA* mutation)LymSFsBlood DNASFs DNA*Sac*II site*Hha*I (exon 1) site/ *Hpa*II (exon 7) site[c](#tf0015){ref-type="table-fn"}*Sac*II site*Hha*I (exon 1) site/ *Hpa*II (exon 7) site[c](#tf0015){ref-type="table-fn"}137yAcroparesthesia, dysmorphism, intellectual disabilities, LVH00611197.984.692.383.6c.36C \> A(p.C12X)\[[@bb0135]\]244yMild cardiomegaly9.92.55.6546.729.735.121.6c.36C \> A(p.C12X)\[[@bb0135]\]342yMild pain9.112.98210.87.41.544.3c.36C \> A(p.C12X)\[[@bb0135]\]411yMild acroparesthesia2.80.828.7170.652.556.840c.36C \> A(p.C12X)\[[@bb0135]\]551yChest pain, acroparesthesia, LVH8.24.721.31146.769.260.170.7c.97G \> T(p.D33Y)This study642yChest pain, LVH4.4--10.61152.369.2----c.97G \> T(p.D33Y)This study739yChest pain, CCF, acroparesthesia5.61.9251272.289.535.559.2c.97G \> T(p.D33Y)This study866yCerebral infraction, CCF, renal failure5.3--35.5185356.9----c.97G \> T(p.D33Y)This study953yChest pain, CCF, acroparesthesia8.5--7.11241.381.7----c.97G \> T(p.D33Y)This study1055yChest pain, cardiomegaly, proteinuria (+)7--7.71028.399.9----c.668G \> C(p.C223S)\[[@bb0140]\]1122yPain in extremities8.8--13.1 (S)131.8------c.668G \> C(p.C223S)\[[@bb0140]\]1245yPain, mild cardiomegaly, proteinuria (++)4.13.717.11374.145.24.8--c.950 T \> C (p.I317T)\[[@bb0220]\]1353yMild pain, mild cardiomegaly, proteinuria (+)4.53.65.81249.774.1--99.9c.950 T \> C (p.I317T)\[[@bb0220]\]1435yPain, cardiomegaly8.30.140982.238.293.8--c.901C \> T (p.R301X)\[[@bb0225]\]1528yAcroparesthesia3.16.826.1577.968.348.7--c.901C \> T (p.R301X)\[[@bb0225]\]1645yHeadache, acroparesthesia, chest pain, LVH4.26.018.21466.7------c.334C \> T (p.R112C)\[[@bb0230]\]1737yMild pain5.55.218145.5----c.1124G \> A(p.G375E)\[[@bb0235]\]1840yMild pain8.91.625.2226.760.6----c.749A \> C(p.Q250P)\[[@bb0240]\]1937yMild pain4--14.2257.4------c.749A \> C(p.Q250P)\[[@bb0240]\]2050yMild proteinuria, mild cardiomegaly9.5--21.5413.952.5----c.1208 T \> C(p.L403S)\[[@bb0245]\]2129yMild cardiomegaly8.8--10.566.978.4----c.658C \> T(p.R220X)\[[@bb0250]\]2230yAsymptomatic3.8--9.7139.7------c.658C \> T(p.R220X)\[[@bb0250]\]2362yCardiomyopathy, pain, proteinuria (+)8.9--15.11652------c.658C \> T(p.R220X)\[[@bb0250]\]245yAsymptomatic4.5--6.2 (S)0Non-meth------c.761delTTGThis study257yAsymptomatic5.5--8.90Non-meth------c.761delTTGThis study2653yAcroparesthesia, headache, cardiac hypertrophy1.8--24.514Meth------c.802delTTAGThis study2772yProteinuria (+++), creatinine clearance (↓), chest pain, cardiomegaly3.41.7141592.1--79.2--c.902G \> A(p.R301Q)\[[@bb0255]\]2874yCCF, cardiac arrhythmia, pacemaker in situ, proteinuria (++)5.13.648.72182.8------c.679C \> T(p.R227X)\[[@bb0260]\]2945yMild pain6.0--25.8794.399.9----c.679C \> T(p.R227X)\[[@bb0260]\]3062yMild pain, LVH8.2--251322.5------IVS3 + 1G \> A\[[@bb0265]\]3144yAsymptomatic----23.1049.4------c.658C \> T(p.R220X)\[[@bb0250]\]3245yMild cardiomegaly4.5--4.1540------c.118C \> T(p.P40S)\[[@bb0270]\]336yAsymptomatic5.4--18.5047.7------c.1019G \> A(p.W340X)\[[@bb0275]\]346yAsymptomatic7.5--13037.5------c.1019G \> A(p.W340X)\[[@bb0275]\]356yAsymptomatic2.2--27283.881.4----c.3G \> A(p.M1I)\[[@bb0280]\]368yAsymptomatic4.5--7.4163.974.9----c.3G \> A(p.M1I)\[[@bb0280]\][^1][^2][^3][^4]

3.4. Quantification of lyso-Gb3 {#s0070}
-------------------------------

Fresh plasma/serum were collected from all subjects, and lyso-Gb3 was extracted in methanol. Three consecutive measurements were performed and averaged. The list is summarized in [Table 1](#t0005){ref-type="table"}.

3.5. Electron microscopy {#s0075}
------------------------

Skin biopsies were taken from the left elbow and prepared for visualization by electron microscopy. Sphingolipid accumulation also varied case by case. Diffuse accumulation was detected in the lysosomes of almost all kind of cells including neuronal Schwann cells, vascular endothelium and fibroblasts ([Fig. 1](#f0005){ref-type="fig"}) in case 1. Mainly vascular endothelial and fibroblastic accumulation were found in cases 5, 7 ([Fig. 2](#f0010){ref-type="fig"}). Sphingolipid accumulation was detected predominantly in exocrine and fibroblastic cells in case 7 and myelin-like deposition was detected primarily in fibroblasts in case 27 ([Fig. 2](#f0010){ref-type="fig"}). Other cases were found to have heterogeneous and irregular or no accumulation (results not shown).Fig. 1Electron micrograph of a section of skin tissue from case 1 showing massive lysosomal accumulation in peripheral neuronal Schwann cells (A), vascular endothelium (B) and fibroblasts (C).Fig. 1Fig. 2In case 7, deposition was detected in the exocrine gland and fibroblastic cells (A, B). Massive and myelin-like depositions were observed in case 27 (C, D).Fig. 2

3.6. Detection of methylation sensitivity for restriction enzyme sites in the GLA gene {#s0080}
--------------------------------------------------------------------------------------

To assess differential methylation, genomic DNA was first treated with a methylation-sensitive endonuclease and then PCR-amplified. After PCR of bisulfite-reacted DNA, almost all the unmethylated cytosines (C) were converted to thymine (T), while methylcytosines were not. When we searched a single methylation-sensitive restriction enzyme site, one *Sac*II site was detected in the 5'UTR, and a cluster of *Hha*I and *Hpa*II sites were detected in exon 1 and 5'UTR of the *GLA* gene. Other exons also contained *Hha*I and *Hpa*II sites; however, only one methylation-sensitive *Hpa*I *RE* site was detected in exon 7 ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Genomic DNA was treated with methylation-sensitive endonuclease and PCR-based amplification was done. Methylation-sensitive *Sac*II, *Hpa*II and *Hha*I were detected in exon 1, the 5'UTR (before and after treatment, A1 and A2, respectively) and exon 7 (before and after treatment, B1 and B2, respectively).Fig. 3

3.7. Quantification of methylation of individual alleles {#s0085}
--------------------------------------------------------

The quantification of methylation was performed based on digestion of mutated or non-mutated alleles by methylation-sensitive *RE*. The digestion of an allele indicated non-methylation. The quantification of methylation of the normal (non-mutated) allele for heterozygous Fabry females was calculated and plotted as a percentage. The quantification is listed in [Table 1](#t0005){ref-type="table"}.

4. Discussion {#s0090}
=============

After the approval of enzyme replacement therapy (ERT), it become the most popular treatment option for Fabry disease. Orally administered pharmacological chaperone migalastat hydrochloride also provide a beneficial effect on *GLA* amenable mutations \[[@bb0150]\]. Recent study showed that \>28% Japanese families had amenable mutations to migalastat \[[@bb0155]\]. However, timing the initiation of therapy is most crucial to get maximum beneficial effects \[[@bb0150],[@bb0160],[@bb0165]\]. The international guidelines for ERT are also being set up for presymptomatic patients \[[@bb0170]\]. The heterozygous female patients manifest wide variety of clinical features, some have mild and some manifest severe phenotypes in early childhood \[[@bb0035],[@bb0040],[@bb0135]\]. Our current study also showed a heterogeneous clinical presentation; one was asymptomatic, and others showed classical phenotypes as Hemizygous males ([Table 1](#t0005){ref-type="table"}).

By measuring α-gal A enzyme activity, the clinical phenotype of heterozygous females cannot be predicted, and lyso-Gb3 was thought to be a useful biomarker for the diagnosis of Fabry disease heterozygotes \[[@bb0175]\]. In this study, we also found similar pictures showed in some severe cases of high enzyme activity ([Table 1](#t0005){ref-type="table"}). Because we used whole cell lysates, which contained both the precursor and mature forms, we could not separate their activities \[[@bb0180],[@bb0185]\]. However, the clinical severity of heterozygous females correlated to the accumulation of lyso-Gb3 ([Table 1](#t0005){ref-type="table"}) and massive sphingolipid accumulation detected by electron microscopy in different cells of skin biopsies ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}).

XCI and skewed XCI favoring the expression of the mutant allele has been proposed as a mechanism to explain the development of severe clinical symptoms in heterozygous Fabry disease and some other X-linked diseases \[[@bb0090],[@bb0190],[@bb0195]\]. The skewed XCI patterns were determined by studying the methylation status of the polymorphic (CAG)n repeat region located within exon 1 of the *HUMARA* gene \[[@bb0090]\] for 29% cases. Our study demonstrated direct evidence of methylation in the *GLA* gene. In most of the cases 27/36 (75%), the methylation of the normal allele (non-mutated allele) directly correlated to the FASTEX severity score ([Fig. 4](#f0020){ref-type="fig"}), probably due to DNA methylation in the *GLA* gene suppressing transcription \[[@bb0200]\]. One allele was mutated, and another allele was methylated in affected females, which caused complete suppression of *GLA* gene transcription and mature α-gal A synthesis. We recently reported that the aberrant DNA methylation of the *GLA* gene is directly associated with autophagy dysfunction \[[@bb0205]\], which caused massive accumulation of sphingolipids and their derivatives. In this study, we found a clear correlation between methylation of the normal allele and accumulation of lyso-Gb3 ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}). Except in cases 4, 24, 25, 28, 29, all the cases were receiving ERT for 3--10 years, and have a significant correlation between the clinical severity FASTEX score, methylation of the normal allele and deposition of lyso-Gb3.Fig. 4Correlation between the patient severity (FASTEX) score and methylation of the normal allele measured by the digestion ratio of mutated and non-mutated alleles by methylation-sensitive *RE Sac*II. The DNA was extracted from blood lymphocytes. Statistical significance was valued as Spearman (ρ) = 0.6333, *p* = .0004.Fig. 4Fig. 5Correlation between the patient lyso-Gb3 accumulation and methylation of the normal allele measured by the digestion ratio of mutated and non-mutated alleles by methylation-sensitive *RE Sac*II. The DNA was extracted from blood lymphocytes. The circle represents mild cases and the square represents severe cases (FASTEX raw score \> 10). Statistical significance was valued as Spearman (ρ) = 0.5271, *p* = .004.Fig. 5

Methylation of the *Sac*II and *Hha*I sites for heterozygous females is highly correlated to the FASTEX severity score and lyso-Gb3 accumulation (statistically significant) \[[Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}\], probably because these sites were close to the promoter region, which contains 474 base pairs of CpG island \[[@bb0130]\]. In some cases (cases 10, 13, 15, 17, 21, and 29) the methylation of the normal allele measured in the *Hpa*II site in exon 7 was correlated to the FASTEX severity score although the statistical significance could not be detected due to a small number of cases.

Several limitations existed in our study. We could not elucidate the phenotype-specific methylation effects, and the severity scores were not recorded when the cases were first diagnosed. We could also not confirm the progression of cardiomyopathy, renal failure or related effects in relation to the methylation ratio of the heterozygous females. However, our current study, which correlated the clinical severity to methylation of the normal allele and accumulation of lyso-Gb3, would be an effective tool for early prediction of phenotypes and early initiation of therapy in females heterozygous for Fabry disease. In addition, several targeted genetic editing techniques were reported in recent years \[[@bb0210],[@bb0215]\]. By detecting the methylation sites in the *GLA* gene, the methylation site can be edited and might allow gene therapy applications for Fabry disease patients.

5. Conclusion {#s0095}
=============

We summarized 36 heterozygous Fabry females with their clinical severity score, their lyso-Gb3 accumulation in plasma and sphingolipid accumulation with skin biopsy. We had detected methylation sensitive *RE* site in exon 7 along with exon 1 and 5\`UTR and of the *GLA* gene. We found a clear correlation between the severity of the phenotype, lyso-Gb3 accumulation and methylation of normal allele detected by non-digestion with methylation sensitive *RE*.
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[^1]: LVH, left ventricular hypertrophy; α-gal A, α-galactosidase A; LYM, lymphocyte; SFs, skin fibroblasts; y, year; −, not measured; Met, methylated; Non-met, non-methylated.

[^2]: α-gal A activity was measured with 4-MU substrate and the normal range of α-gal A activity was 10--12 nmol/h/mg protein in lymphocytes and skin fibroblasts. Blood lymphocytes were collected to measure the enzyme activity before two weekly enzyme infusions for patients who were in ERT.

[^3]: Lyso-Gb3 was measured in the plasma of all the patients except in cases 11 and 24. Their Lyso-Gb3 was measured in blood serum. The normal range of Lyso-Gb3 in plasma/ serum was considered \<2.1 ± 2 nmol/L.

[^4]: Methylation of the *Hha*I site was measured in exon 1 for the patients who have exon 1 mutations including cases 1--9, and 35--36, and methylation of the *Hpa*II site was measured in exon 7 for the patients who have exon 5--7 mutations including cases 10, 12--15, 17--18, 20--21, and 29.
